Advanced Cell Diagnostics Provider of the most advanced RNA in situ hybridization technology Contact Us Technology Technology Overview How RNAscope Assay Works Why use RNA-based Biomarkers? Challenges of Protein-based Biomarkers Challenges of DNA-based Biomarkers Applications Applications Overview Areas of Interest Cancer HPV Related Cancer Neuroscience Infectious Disease RTKs & PI-3-Kinase Signaling Wnt & Stem Cell Signaling Research Solutions Non-coding RNA No Antibody No Problems Single Cell Analysis Gene Fusions Science Publications All Publications Featured Publications Data Library Image Gallery Featured Images Scientific Posters Presentations Webinars Archive Diagnostics Diagnostics Overview ACD Diagnostics Pipeline ACD Clinical Studies Products Products Overview Probes & Systems for Hybridization Overview RNAscope Probe Search Target Probes: Catalog Target Probes: Custom HybEZ Hybridization Products EZ-Batch™ Slide Processing System Manual Assays for Amplification Overview RNAscope 2.0 High Definition - BROWN RNAscope 2.0 High Definition - RED RNAscope 2-Plex Chromogenic RNAscope Multiplex Fluorescent Automated Assays for Amplification Overview RNAscope Assay for Leica System RNAscope Assay for Ventana Systems Microscopes for Visualization Overview Fluorescent Imaging Software for Quantification Products for Quality Control Services Services Overview Assay Services by ACD Biomarker Validation Assay Development Quantitative Analysis Assay Services by CLIA-Certified Providers Assay Services by Preclinical CROs Support Support Overview Downloads Product Information & Manual Brochures Scientific Posters Application Spotlights Probe Lists Publication List Positive & Negative Control Images Tissue Requirements & Troubleshooting Tips Frequently Asked Questions (FAQs) Online Training Videos Company Company Overview Leadership News and Events Contact Us Distributors Blog Careers A Novel Chromogenic In Situ Hybridization Assay for FGF23 mRNA in Phosphaturic Mesenchymal Tumors., Carter JM, Caron BL, Dogan A, Folpe AL., American Journal of Surgical Pathology, 2014 July 14 --- Oncofetal Long Noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2, Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, Yang N, Zhou WP, Li WL, Li W, Sun SH, Hepatology, 2014 July 12 --- X-inactivation normalizes O-GlcNAc Transferase levels and generates an O-GlcNAc-depleted Barr body, Olivier-van Stichelen, S, J. A. Hanover, Frontiers in Genetics, 2014 July 11 --- Early colonizing Escherichia coli elicits remodeling of rat colonic epithelium shifting toward a new homeostatic state., Tomas J, Reygner J, Mayeur C, Ducroc R, Bouet S, Bridonneau C, Cavin JB, Thomas M, Langella P, Cherbuy C., ISME J., 2014 July 11 --- Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome., Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S., J Clin Invest, 2014 July 01 --- Human Conchal Cartilage and Temporal Fascia: An Evidence-based Roadmap from Rhinoplasty to an In Vivo Study and Beyond., Cimpean AM, Crăiniceanu Z, Mihailovici D, Bratu T, Raica M., In Vivo. , 2014 July 01 --- PROX1 Expression in Gastric Cancer: From Hypothesis to Evidence., Taban O, Cimpean AM, Raica M, Olariu S., Anticancer Res., 2014 July 01 --- Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma, Liu JL, Chen FF, Lung J, Lo CH, Lee FH, Lu YC, Hung CH., Br J Cancer., 2014 July 01 --- In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients, Vassilakopoulou M, Togun T, Dafni U, Cheng H1, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A., PLoS One., 2014 June 24 --- Functional ex vivo assay to select Homologous Recombination deficient breast tumors for PARP inhibitor treatment, Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens J, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter J, Vreeswijk M, Jager A, van Gent DC., Clin Cancer Res., 2014 June 24 --- HOW IT WORKS FEATURED PUBLICATIONS FEATURED APPLICATIONS FIND PROBE CHOOSE ASSAY REVOLUTIONARY RNASCOPE® RNA IN SITU HYBRIDIZATION TECHNOLOGY FEATURED IMAGE GALLERY Delivers Quantitative Molecular Detection and Morphological Context (MD & MC) in a Single Assay RNAscope® Technology is a cutting-edge multiplex nucleic acid in situ hybridization technology, based on ACD’s unique, patented probe design strategy which enables simultaneous signal amplification and background noise suppression. RNAscope Technology represents one of the most significant advances in ISH technology in over 40 years. What is the value of Quantitative Molecular Detection and Morphological Context (MD & MC) in a single assay? What makes RNAscope unique? Molecular Detection: RNAscope detects single RNA molecules and provides quantitative analysis of gene expression at the single-cell resolution. Morphological Context: RNAscope localizes RNA molecules providing spatial and cell-specific expression while preserving tissue architecture. Quantitative: RNAscope quantifies RNA molecules per cell, giving accurate expression level at the single cell resolution across heterogeneous cell populations. Universal: RNAscope's patented probe design can be applied to virtually ANY gene in ANY genome in ANY tissue. Scalable: The assay is robust and easy to implement in basic, translational and clinical research labs. Availability of Manual Assays, Automated Assays and Assay Services provide ultimate flexibility. RNAscope enables in situ detection of RNA biomarkers—filling a long standing gap in in situ molecular analysis. RNAscope can complement IHC when antibodies are unavailable or have insufficient sensitivity or uncertain specificity. RNAscope is ideal for detecting RNAs for secreted proteins and non-coding RNA—a limitation of IHC. Downstream of microarrays and NGS (e.g., RNA-seq), RNAscope is an ideal platform for translating new scientific advances into clinical applications due to the speed of RNAscope assay development and its superior sensitivity and specificity. Other RNA biomarker analysis methods such as RT-PCR can provide quantitative, sensitive and specific measurements of RNA transcripts. However, the resulting quantitative gene expression information is without morphological and cellular context and only represents a “group average” of an admixture of heterogeneous populations of cells. RNAscope’s ability to provide gene expression at the single cell resolution coupled with morphological context is well-suited for RNA analysis in tissue diagnostics applications. MORE NEWS July 15, 2014 Advanced Cell Diagnostics RNAscope® in situ hybridizationtechnology gains significant traction June 17, 2014 European Webinar: RNAscope® - a novel breakthrough RNA in situ hybridization platform December 8, 2013 Advanced Cell Diagnostics Announces Election of Dr. Joseph D. Keegan to its Board of Directors EVENTS December 02, 2014 The 2014 Pathology Congress Booth # November 18, 2014 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Booth D01 November 16, 2014 SFN 2014 - Society for Neuroscience Annual Meeting Booth # 3111 REQUEST A DEMO Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Asia-Pacific Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burma (Myanmar) Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Croatia (Hrvatska) Cuba Cyprus Czech Republic Czechoslovakia (former) Democratic Republic of Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Great Britain (UK) Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea (North) Korea (South) Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montserrat Morocco Mozambique Namibia Nauru Nepal Netherlands Netherlands Antilles Neutral Zone New Caledonia New Zealand (Aotearoa) Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palestinian Territory, Occupied Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Private Puerto Rico Qatar Reunion Republic of Serbia Romania Russia Rwanda S. Georgia and S. Sandwich Isls. Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovak Republic Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka St. Helena St. Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City State (Holy See) Venezuela Viet Nam Virgin Islands (British) Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia Zambia Zimbabwe Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Virgin Islands Washington West Virginia Wisconsin Wyoming Send Terms and Conditions of Sale Copyright © 2014 Advanced Cell Diagnostics. View our terms of service and terms and conditions of sale. | Designed by Audacity | Biotech Consulting SEO by Supreme Optimization Share For Molecular Biology Applications (MBA), not intended for diagnosis. RNAscope®, RNAscopeVS™, CTCscope™, DNAscope™, RNAflow™, No Antibody No Problem™, Why Wait?™, and Now You Can See Any RNA™ are registered trademarks or trademarks of Advanced Cell Diagnostics, Inc. in the United States or other countries. All rights reserved. ©2014 Advanced Cell Diagnostics, Inc.